Search company, investor...

Stage

Series B | Alive

Total Raised

$14.57M

Last Raised

$11.97M | 5 yrs ago

About Acousia Therapeutics

Acousia Therapeutics is a biotech company that experiments with small molecules for treatment of hearing loss. Sensory hair cells are the key cells for hearing in the inner ear. Acousia`s approach will help to replace lost hair cells by cellular regeneration originating from supporting cells.

Headquarters Location

Sindelfinger Straße 3

Tubingen, 72070,

Germany

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Acousia Therapeutics Patents

Acousia Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • Audiology
  • Auditory system
  • Ear
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/27/2018

6/15/2021

Ion channels, Auditory system, Ear, Prodrugs, Audiology

Grant

Application Date

2/27/2018

Grant Date

6/15/2021

Title

Related Topics

Ion channels, Auditory system, Ear, Prodrugs, Audiology

Status

Grant

Latest Acousia Therapeutics News

Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September

Aug 23, 2023

Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia Therapeutics has been invited to contribute two presentations at the 3rd Annual Inner Ear Disorders Therapeutics Summit in Boston (MA). “Key Factors in Preclinical Study Design for Enhancing Probability of Translational Success” and “Emerging Trends in Drug Development for Age-Related Hearing Loss” will both include learnings from the company’s outer hair cell targeting Kv7.4 activator development programs, which are in the clinical (ACOU085) and late preclinical stages (ACOU082). Dr. Jonas Dyhrfjeld-Johnsen, Chief Development Officer of Acousia Therapeutics, will also participate in the panel discussion “Understanding how the Differences in Chosen Animal Model and Human Hearing Development Impacts Preclinical Efficacy and Translational Success”. On September 2, the company has been invited to present the talk “ACOU085 – Lessons Learned from Developing a Locally Administered Otoprotectant” at the 2023 Hearing Therapeutics Summit organized by the Royal National Institute for Deaf People (RNID), University College London Ear Institute, and National Institute for Health and Care Research in London. Acousia Therapeutics, along with its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen), will then attend The 58th Inner Ear Biology Workshop & Symposium (IEB 2023) in London from September 3–5, where they will present data from the ACOU082 development program in the “ACOU082: A Systemically Administered Kv7.4 Activator Drug Candidate Uniquely Suited for the Treatment and Prevention of Age-Related Hearing Loss” presentation. ACOU085 is a proprietary, small-molecule, etiology-agnostic otoprotective drug candidate. It recently completed a successful first-in-man clinical Phase 1b study using the standard transtympanic administration of a slow-release gel formulation. ACOU085 is expected to enter Phase 2a clinical testing for the prevention of chemotherapy-induced hearing loss and outer hair cell apoptosis in cancer patients by Q4 2023. ACOU082 is a proprietary, small-molecule Kv7.4 developed for oral administration. It has the potential to both acutely enhance natural hearing and preserve hearing capacity for people with chronic, progressive disorders like e.g. age-related hearing loss. Kv7.4 channels are strongly expressed in the sensory, outer hair cells of the cochlea, where they not only influence outer hair cell amplification and frequency discrimination to maintain hearing function, but also provide homeostatic resistance to deleterious insults, including e.g. drug-induced ototoxicity, noise exposure, and aging. About Acousia Therapeutics GmbH Acousia Therapeutics GmbH is a privately-held, clinical stage biotech company in Tübingen, Germany dedicated to the identification and development of small molecules for the effective prevention and treatment of different etiologies of hearing loss. Acousia Therapeutics develops drugs for local and systemic administration. Rückfragen & Kontakt: Über apa-ots APA-OTS ist Österreichs stärkster Verbreiter von multimedialen Presseinformationen in Text, Bild, Video und Audio im In- und Ausland. OTS-Aussendungen werden ausschließlich unter inhaltlicher Verantwortung des jeweiligen Aussenders/der Aussenderin verbreitet; diese/r muss im Rückfragehinweis eindeutig erkennbar sein. APA-OTS selbst nimmt keine inhaltlichen Einordnungen oder Beurteilungen der verbreiteten Inhalte vor.

Acousia Therapeutics Frequently Asked Questions (FAQ)

  • Where is Acousia Therapeutics's headquarters?

    Acousia Therapeutics's headquarters is located at Sindelfinger Straße 3, Tubingen.

  • What is Acousia Therapeutics's latest funding round?

    Acousia Therapeutics's latest funding round is Series B.

  • How much did Acousia Therapeutics raise?

    Acousia Therapeutics raised a total of $14.57M.

  • Who are the investors of Acousia Therapeutics?

    Investors of Acousia Therapeutics include KfW, Boehringer Ingelheim Venture Fund, LBBW Venture Capital, Bregua, Creathor Ventures and 3 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.